News Detail
NEW DELHI, 12 DEC 2024: Drug maker Cipla on Wednesday said it has received approval from the Central Drugs Standard Control Organisation for the distribution and marketing of Afrezza inhalation powder in India.
Afrezza, a product created and manufactured by......
View Details
Source : Business Standard
Cipla
Afrezza
insulin inhalation
diabetes management
CDSCO approval
non-injectable insulin
type 1 diabetes
type 2 diabetes
rapid-acting insulin
India diabetes care
MannKind Corporation
insulin for diabetes
Related News
- Sun Pharma unit Taro to acquire 100% stake in Antibe Therapeutics (16-01-2025)
- Calcutta HC directs Paschim Banga Pharmaceuticals to stop manufacturing; state to compensate families (16-01-2025)
- FDA Revokes Use of 'FD&C Red No.3' in Foods and Drugs (16-01-2025)
- Dabur sues Patanjali over toothpaste trade dress (16-01-2025)
- Wrappers of drug brands found from Paonta printing press premises (16-01-2025)
- PCI revises list of pharmacists blocked on DIGI-PHARMed platform, asks to re-register (16-01-2025)
- Clear labelling of industrial & medical oxygen must, PMO tells health ministry (16-01-2025)
- Himachal to form Special Task Force to Combat Drug Abuse (16-01-2025)
- SC warns States/UTs of Contempt Proceedings over inaction on Misleading Advertisements (16-01-2025)
- 3600 Proxyvon capsule consignment going to Nepal caught (15-01-2025)